Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's...

|By:, SA News Editor

Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's initiating its first phase 3 trial of cabozantinib for patients with a particular type of prostate cancer. Without an agreement with the FDA, the company's not pursuing a special protocol assessment from the agency.